Physician profile
Luis G Castro
NPI 1396902789
$1,304.82
in general payments reported to CMS, 2019-2025
24 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2020: $302 · 2021: $126 · 2022: $73.55 · 2023: $195 · 2024: $300 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $650 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.79 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $236.40 | 2023-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $149.30 | 2020-2023 | Jardiance, Emgality, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.31 | 2020 | |
| Novo Nordisk INC | $127.48 | 2019-2024 | Ozempic, Rybelsus |
| Depuy Synthes Sales INC. | $68.01 | 2023-2025 | Peak, Orthovisc |
| Abbott Laboratories | $66.09 | 2024-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $56.26 | 2019-2021 | |
| Abbvie INC. | $56.23 | 2021-2025 | |
| Pacira Therapeutics, INC. | $53.63 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.71 | 2023 | |
| Baxter Healthcare | $38.31 | 2022 | |
| Exact Sciences Corporation | $34.68 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $30.57 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $26.10 | 2019 | |
| Ibsa Pharma INC. | $21.05 | 2023 | Tirosint, Licart |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $19.90 | 2024 | |
| Gilead Sciences, INC. | $19.46 | 2021 | |
| Glaxosmithkline, LLC. | $19.36 | 2019 | |
| Astellas Pharma US INC | $18.64 | 2024 | Veozah |
| Pacira Pharmaceuticals Incorporated | $18.60 | 2024 | Iovera, Zilretta |
| Sanofi Pasteur INC. | $18.11 | 2022 | |
| Mannkind Corporation | $16.40 | 2019 | |
| Exeltis, USA INC. | $14.81 | 2024 | Tyblume |
| Janssen Pharmaceuticals, INC | $14.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.